Blood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting), By Product (Reagent, Instrument), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.88 Billion
CAGR (2026-2031)	5.57%
Fastest Growing Segment	Reagent
Largest Market	North America
Market Size (2031)	USD 6.76 Billion

Market Overview

The Global Blood Screening Market will grow from USD 4.88 Billion in 2025 to USD 6.76 Billion by 2031 at a 5.57% CAGR. The Global Blood Screening Market encompasses the rigorous analysis of donated blood and plasma to identify infectious pathogens and confirm compatibility before transfusion. Market expansion is principally driven by the increasing global incidence of transfusion-transmissible infections and strict regulatory mandates enforcing blood safety protocols. Furthermore, the rising demand for blood products in surgical and trauma care significantly necessitates robust screening volumes across major healthcare networks.

Nevertheless, the substantial expense associated with advanced molecular testing platforms creates a barrier to entry for price-sensitive healthcare systems in emerging regions. This economic challenge hampers the adoption of premium screening technologies despite their proven safety benefits. According to the Association for the Advancement of Blood & Biotherapies, in March 2025, data showed that 11.58 million red blood cell units were collected in the United States during 2023, illustrating the immense operational scale and funding required to secure the blood supply in developed markets.

Key Market Drivers

The Rising Prevalence of Infectious and Chronic Diseases acts as a primary catalyst for the blood screening market, necessitating rigorous pathogen detection to ensure transfusion safety. As viral burdens increase globally, healthcare systems are compelled to implement stringent nucleic acid amplification testing (NAT) and immunoassay protocols to intercept HIV, Hepatitis B, and Hepatitis C before they enter the supply chain. This urgency is underscored by the escalating mortality rates associated with these infections. According to the World Health Organization, April 2024, in the 'Global Hepatitis Report 2024', viral hepatitis claimed 1.3 million lives in 2022, a statistic that reinforces the critical imperative for advanced screening measures to prevent transmission through blood products and reduce this growing disease burden.

Escalating Global Demand for Donated Blood and Transfusions further accelerates market reliance on efficient high-throughput screening solutions, particularly as donor availability fluctuates. The pressure to maximize the utility of every collected unit drives the adoption of automated platforms that reduce discard rates and ensure rapid turnaround times for emergency procedures. However, maintaining adequate inventories remains a significant operational challenge. According to the American Red Cross, January 2024, in the 'Emergency Blood Shortage' press release, the number of people donating blood fell by approximately 40% over the last 20 years, creating a supply crisis that heightens the importance of error-free screening to prevent wastage. Highlighting the sheer volume of diagnostic activity required to support global health, according to Roche, in 2024, the company reported that 29 billion diagnostic tests were delivered to customers worldwide during the prior year.

Download Free Sample Report

Key Market Challenges

The substantial expense associated with advanced molecular testing platforms constitutes a primary restraint on the Global Blood Screening Market, particularly within price-sensitive healthcare systems in emerging economies. These high operational costs create a significant barrier to entry, preventing the widespread adoption of premium screening technologies that are standard in developed nations. Consequently, laboratories in resource-limited settings often rely on less expensive, older testing methods or forgo comprehensive screening entirely. This economic disparity directly hampers market growth by limiting the addressable market for manufacturers of advanced assay kits and automated instrumentation, effectively confining their primary revenue streams to established, wealthy healthcare networks.

According to the International Society of Blood Transfusion, in 2024, data indicated that approximately 20% of blood donations in the Sub-Saharan African region remained untested for transfusion-transmissible infections due to severe financial and infrastructure constraints. This statistic underscores the profound impact of cost barriers, as the inability to fund essential screening protocols locks a substantial portion of the global population out of the advanced blood screening market. As long as these fiscal limitations persist, the market’s expansion into developing regions will remain stunted.

Key Market Trends

The expansion of extended blood group genotyping is transforming the market by enabling precise donor-recipient matching beyond standard ABO and Rh compatibility. This shift is critical for preventing alloimmunization in chronically transfused patients, such as those with sickle cell disease, by identifying minor antigen variants that traditional serology often misses. As laboratories increasingly prioritize transfusion safety to mitigate adverse reactions, the demand for advanced molecular typing solutions has surged effectively. According to Grifols, February 2025, in the 'Grifols delivers a strong 2024' press release, the company reported total annual revenue growth of 10.3% at constant currency, explicitly identifying the Blood Typing Solutions business as a primary driver with double-digit gains in key markets.

Concurrently, there is a definitive shift towards automated and high-throughput screening platforms designed to streamline laboratory operations and manage rising testing volumes. By integrating multiple assay steps—from sample preparation to result analysis—into single modular systems, blood centers can significantly reduce manual errors and operational costs while improving turnaround times. This trend is further supported by the need for scalable solutions in centralized testing facilities that process vast quantities of donor samples daily. According to Roche, January 2025, in the 'Annual Report 2024', sales in the Diagnostics Division increased by 4%, driven largely by the strong global uptake of high-throughput immunodiagnostic and molecular solutions that enhance laboratory efficiency.

Segmental Insights

The reagents segment represents the fastest-growing category within the global blood screening market, driven by the high frequency of consumption associated with these essential products. This rapid expansion is largely attributed to the rising volume of global blood donations which necessitates continuous procurement of screening supplies. Additionally, stringent safety protocols established by regulatory authorities such as the U.S. Food and Drug Administration mandate rigorous testing for infectious diseases, ensuring a sustained demand for specific chemical agents. Consequently, the recurring requirement for reagents in every screening procedure fuels their superior market performance compared to capital equipment.

Regional Insights

North America leads the global blood screening market due to its established healthcare infrastructure and strict safety protocols. This dominance is driven by mandates from the U.S. Food and Drug Administration requiring rigorous testing of donated blood for infectious diseases. The region also benefits from the presence of major diagnostic manufacturers, which facilitates the integration of automated screening solutions. Furthermore, high awareness regarding transfusion-transmittable infections among medical professionals supports the consistent demand for effective testing products across the United States and Canada.

Recent Developments

• In October 2025, QuidelOrtho Corporation highlighted the recent FDA approval of its MTS DAT Card during the Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. This new product completes the company’s gel-based portfolio for direct antiglobulin testing, a critical procedure in immunohematology for detecting antibodies attached to red blood cells. When paired with the company's automated vision platforms, the card allows laboratories to automate and standardize the direct antiglobulin test, improving workflow efficiency and ensuring reliable, timely results for pre-transfusion compatibility testing and patient care.
• In April 2025, the Chairman and CEO of Abbott Laboratories announced the company's strategic entry into the molecular nucleic acid testing (NAT) segment of the global blood screening market with the development of a new system called Alinity n. This announcement was part of a broader $500 million investment aimed at expanding the company's diagnostic manufacturing and research capabilities. The Alinity n system is designed to screen blood donations for infectious diseases by detecting DNA and RNA, complementing the company’s existing serological screening technologies and positioning it to capture a larger share of the comprehensive blood safety market.
• In June 2024, Grifols announced the commercial availability of the Procleix ArboPlex Assay in markets accepting the CE Mark, representing a significant advancement in transfusion medicine. This automated nucleic acid testing (NAT) solution is the first to simultaneously detect and differentiate four major mosquito-borne arboviruses—dengue, Zika, chikungunya, and West Nile—from a single plasma or serum sample. By consolidating testing for these emerging pathogens onto the Procleix Panther System, the assay enables blood centers to streamline laboratory operations and enhance the safety of the blood supply against seasonally and geographically variable infectious threats.
• In March 2024, Roche received approval from the U.S. Food and Drug Administration (FDA) for the cobas Malaria test, becoming the first molecular assay intended to screen blood donors for malaria in the United States. Designed for use on the company's automated high-throughput systems, this qualitative in vitro nucleic acid screening test allows for the direct detection of RNA and DNA from the five main species of Plasmodium parasites in whole blood samples. This regulatory milestone addresses a critical need in blood safety, offering a more sensitive alternative to traditional serological and microscopic methods for donor screening.

Key Market Players

• Abbott
• Roche Diagnostics
• Bio-Rad
• Siemens Healthineers
• Grifols
• Ortho Clinical Diagnostics
• QuidelOrtho
• Thermo Fisher
• DiaSorin
• Beckman Coulter

By Technology	By Product	By Region
Nucleic Acid Amplification Test (NAT) ELISA Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) Next Generation Sequencing (NGS) Western Blotting	Reagent Instrument	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Screening Market, By Technology:

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing (NGS)
• Western Blotting

• Blood Screening Market, By Product:

• Reagent
• Instrument

• Blood Screening Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE